Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATBPD Antibe Therapeutics		$0.22	$2.64 ▼ $3.50	$1.21B	0.57	29,710 shs	N/A
INVA Innoviva	$18.77 -1.5%	$19.79	$16.67 ▼ $22.00	$1.20B	0.37	704,540 shs	764,766 shs
KNSA Kiniksa Pharmaceuticals International	$28.09 -3.0%	$27.71	$17.82 ▼ $30.69	$2.11B	0.05	556,059 shs	355,269 shs
MGNX MacroGenics	$1.61 +1.9%	$1.48	$0.99 ▼ $5.77	$99.68M	1.59	849,397 shs	764,998 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATBPD Antibe Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
INVA Innoviva	-0.57%	-0.73%	-11.47%	+8.79%	+13.59%
KNSA Kiniksa Pharmaceuticals International	+0.52%	+3.93%	-2.75%	+49.92%	+38.12%
MGNX MacroGenics	-0.63%	+9.72%	-11.24%	+22.48%	-63.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATBPD Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	4.3254 of 5 stars	3.5	0.0	0.0	4.2	3.1	1.7	1.9
KNSA Kiniksa Pharmaceuticals International	3.6147 of 5 stars	3.5	4.0	0.0	0.0	2.8	3.3	0.6
MGNX MacroGenics	4.144 of 5 stars	3.2	3.0	0.0	4.4	1.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATBPD Antibe Therapeutics	0.00	N/A	N/A	N/A
INVA Innoviva	3.00	Buy	$40.50	115.77% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	40.03% Upside
MGNX MacroGenics	2.40	Hold	$5.71	254.92% Upside

Current Analyst Ratings Breakdown

Latest INVA, KNSA, MGNX, and ATBPD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/16/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATBPD Antibe Therapeutics	$7.51M	0.00	N/A	N/A	$0.10 per share	0.00
INVA Innoviva	$358.71M	3.29	$3.38 per share	5.56	$11.03 per share	1.70
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.84	N/A	N/A	$6.60 per share	4.26
MGNX MacroGenics	$149.96M	0.68	N/A	N/A	$1.85 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATBPD Antibe Therapeutics	-$14.54M	-$0.60	N/A	N/A	N/A	-273.96%	-150.49%	-98.51%	N/A
INVA Innoviva	$23.39M	-$1.01	N/A	12.11	N/A	-16.15%	15.77%	8.41%	7/29/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	0.00	112.36	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)

Latest INVA, KNSA, MGNX, and ATBPD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
7/29/2025	Q2 2025	INVA Innoviva	$0.43	N/A	N/A	N/A	$87.10 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATBPD Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATBPD Antibe Therapeutics	N/A	5.97	5.42
INVA Innoviva	0.40	2.48	2.30
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
MGNX MacroGenics	N/A	3.28	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATBPD Antibe Therapeutics	N/A
INVA Innoviva	99.12%
KNSA Kiniksa Pharmaceuticals International	53.95%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ATBPD Antibe Therapeutics	N/A
INVA Innoviva	2.25%
KNSA Kiniksa Pharmaceuticals International	53.48%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATBPD Antibe Therapeutics	47	387.00 million	N/A	Not Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable

INVA, KNSA, MGNX, and ATBPD Headlines

Recent News About These Companies

MacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the company

July 11 at 11:45 AM | finance.yahoo.com

MacroGenics (NASDAQ:MGNX) Share Price Crosses Below 200-Day Moving Average - Here's Why

July 8 at 4:34 AM | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of "Hold" from Analysts

July 4, 2025 | americanbankingnews.com

MacroGenics, Inc. (MGNX) Latest Stock News & Headlines - Yahoo Finance Canada

June 29, 2025 | ca.finance.yahoo.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Analysts

June 29, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Stock Rating Lowered by Wall Street Zen

June 27, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

June 18, 2025 | marketbeat.com

MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead

June 16, 2025 | investing.com

MacroGenics lands $70M 'infusion of cash' to advance clinical programs

June 13, 2025 | bizjournals.com

MacroGenics: Working On That Road To Recovery

June 11, 2025 | seekingalpha.com

MacroGenics Shares Rise on Royalty-Purchase Agreement

June 10, 2025 | marketwatch.com

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

June 10, 2025 | globenewswire.com

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

June 3, 2025 | globenewswire.com

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

May 23, 2025 | nasdaq.com

4 Medical Product Stocks to Watch From a Challenging Industry

May 21, 2025 | zacks.com

6MGNX : 4 Analysts Assess Macrogenics: What You Need To Know

May 20, 2025 | benzinga.com

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 16, 2025 | finanznachrichten.de

Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50

May 16, 2025 | finance.yahoo.com

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

May 13, 2025 | zacks.com

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

A Look at Macrogenics's Upcoming Earnings Report

May 12, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA, KNSA, MGNX, and ATBPD Company Descriptions

Antibe Therapeutics OTCMKTS:ATBPD

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Innoviva NASDAQ:INVA

$18.77 -0.29 (-1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$17.86 -0.91 (-4.84%)

As of 07:45 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.09 -0.86 (-2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$28.24 +0.15 (+0.52%)

As of 08:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

MacroGenics NASDAQ:MGNX

$1.61 +0.03 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$1.61 0.00 (0.00%)

As of 07:28 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time